抗耐药结核新药贝达喹啉、德拉马尼和普托马尼的药动学特征及药物相互作用研究进展  

Research progress on pharmacokinetic and drug-drug interaction of new anti-drug-resistant tuberculosis drugs bedaquiline,delamanid,and pretomanid

作　　者：丁杨明 陆宇 Ding Yang-ming;Lu Yu(Beijing Key Laboratory of Drug Resistance Tuberculosis Research,Beijing Chest Hospital,Capital Medical University,Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing 101149)

机构地区：[1]首都医科大学附属北京胸科医院药物学研究室、北京市结核病胸部肿瘤研究所耐药结核病北京市重点实验室,北京101149

出　　处：《中国抗生素杂志》2023年第3期351-356,共6页Chinese Journal of Antibiotics

基　　金：国家自然科学基金(No.82173862);北京市医院管理中心临床医学发展专项经费(No.ZYLX202123)

摘　　要：结核病(Tuberculosis,TB)是人类健康的主要威胁之一,多药组合的化学治疗是控制结核病的主要手段。近年贝达喹啉(Bedaquiline,BDQ)、德拉马尼(Delamanid,DLM)、普托马尼(Pretomanid,PMD)等抗耐药结核新药的出现,显著提高了耐药结核的治愈率。了解抗耐药结核新药的药动学特征及药物相互作用特点,合理设计药物组合及给药方案,可以减少药物不良反应发生,提高治疗成功率。本文对三种主要抗耐药结核新药的代谢动力学及药物相互作用研究进行综述,旨在为临床治疗提供依据和参考。Tuberculosis(TB)is one of the most threats to human health,Chemotherapy with regimen of anti-tuberculosis drugs is the main means of controlling tuberculosis.The emergence of new anti-drug-resistant tuberculosis drugs such as bedaquiline,delamanid,and pretomanid has significantly increased the cure rate of drugresistant tuberculosis.Research on the pharmacokinetics and drug-drug interactions of new anti-drug-resistant tuberculosis drugs,and designing drug and dosing regimens can reduce the incidence of adverse drug reactions and enhance the possibility of successful drug-resistant tuberculosis treatment.This article reviews the studies on the metabolism and drug interactions of three major new anti-drug-resistant tuberculosis drugs in recent years that provide a basis for clinical treatment and follow-up research.

关 键 词：贝达喹啉 德拉马尼 普托马尼 药动学 药物相互作用 

分 类 号：R978.3[医药卫生—药品]